

Table S5. Relationship Between Cancer Cell-LC3 Expression and Clinicopathologic Factors

Characteristics		LC3 ⁺ cancer cells low	LC3 ⁺ cancer cells high	<i>P</i> value
		n=19 (48.7 %)	n=20 (51.3 %)	
Age	<70	12 (63 %)	7 (35 %)	0.0787
	≥ 70	7 (37 %)	13 (65 %)	
Sex	Male	9 (47 %)	10 (50 %)	0.8695
	Female	10 (53 %)	10 (50 %)	
pT category	pT1/pT2	4 (21 %)	1 (5 %)	0.1339
	pT3/pT4	15 (79 %)	19 (95 %)	
Lymph node metastasis	No	10 (53 %)	7 (35 %)	0.267
	Yes	9 (47 %)	13 (65 %)	
UICC stage	I	4 (21 %)	0 (0 %)	0.0769
	II	12 (63 %)	14 (70 %)	
	III	3 (16 %)	6 (30 %)	
Perilymphatic invasion	No	15 (79 %)	10 (50 %)	0.0596
	Yes	4 (21 %)	10 (50 %)	
Perivascular invasion	No	16 (84 %)	11 (55 %)	0.0482
	Yes	3 (16 %)	9 (45 %)	
Perineural invasion	No	5 (26 %)	3 (15 %)	0.3817
	Yes	14 (74 %)	17 (85 %)	
CEA (ng/ml)	<5.0	14 (74 %)	17 (85 %)	0.3817
	≥ 5.0	5 (26 %)	3 (15 %)	
CA19-9 (U/ml)	<37.0	10 (56 %)	8 (40 %)	0.429
	≥ 37.0	9 (44 %)	12 (60 %)	

The χ^2 test was performed to analyze correlations between LC3 expression in the immunohistochemical analyses and the clinicopathologic characteristics.